Resalis Therapeutics presented data and preclinical rationale for an antisense oligonucleotide (ASO) targeting miR‑22 that it says produces precision weight loss and metabolic benefits, positioning the therapy as an alternative to GLP‑1 peptide drugs. Company presentations at TIDES Europe described mechanisms that alter fat metabolism rather than appetite suppression. Resalis’ CSO Riccardo Panella outlined mouse-model evidence showing protection from weight gain and metabolic improvements when miR‑22 is inhibited. The firm argues the ASO could avoid some long-term limitations of GLP‑1s such as muscle and bone impacts and treatment discontinuation. The development underscores growing industry interest in oligonucleotide modalities for systemic metabolic diseases. If Resalis advances into clinical trials, the program will test whether tissue-level modulation of fat biology can deliver durable, safe weight loss in humans.